semaglutide gallatin tn TennCare's obesity medication coverage is a win for Tennesseans • Tennessee Lookout TOP 10 BEST Semaglutide in

L., and Cai, G

This has prompted TikTok to actively crack down on content promoting weight loss products on its app starting this month as part of its new community guidelines

Key Takeaways Gastrointestinal events are the most common adverse effects: Nausea, diarrhea, and vomiting were reported in 4067% of participants at higher doses in published Phase 2 trial data Adverse events are dose-dependent: Higher retatrutide doses consistently produced higher rates of GI events across all published trials Most adverse events were mild to moderate: The Phase 2 trial reported the majority of events as Grade 1-2 in severity Discontinuation rates ranged from 610%: Published data shows dropout rates due to adverse events were comparable to other GLP-1 class compounds Retatrutide is not FDA-approved: All safety data comes from investigational clinical trials it remains a research compound What Clinical Trials Tell Us About Retatrutide Adverse Events Retatrutide (LY3437943) is an investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously

Wegovy has been approved by the US Food and Drug Administration as a weight loss drug for adults who are obese, defined as a person whose BMI is greater than 30, as well as for people with a BMI of at least 27 who also have a weight-related condition, such as high blood pressure

Without it, even the best medicine for weight loss cannot function optimally